Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | IDH1 R132X |
| Therapy | Ivosidenib |
| Indication/Tumor Type | chondrosarcoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH1 R132X | chondrosarcoma | sensitive | Ivosidenib | Phase I | Actionable | In a Phase I trial, Tibsovo (ivosidenib) treatment demonstrated manageable toxicity and resulted in an objective response rate of 23.1% (3/13, 1 complete, 2 partial responses) with a median duration of response of 53.5 months and a median progression-free survival of 7.4 months in patients with conventional chondrosarcoma harboring IDH1 mutations including R132C (n=7), R132G (n=2), R132L (n=1), or R132S (n=1) (PMID: 40100120). | 40100120 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40100120) | Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma. | Full reference... |